FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 235 filers reported holding FATE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $174,688 | -58.6% | 17,313 | -8.0% | 0.00% | -50.0% |
| Q3 2022 | $422,000 | -3.2% | 18,828 | +7.1% | 0.00% | 0.0% |
| Q2 2022 | $436,000 | -33.7% | 17,581 | +3.5% | 0.00% | -33.3% |
| Q1 2022 | $658,000 | -36.5% | 16,980 | -4.2% | 0.00% | -25.0% |
| Q4 2021 | $1,037,000 | -0.5% | 17,727 | +0.8% | 0.00% | -20.0% |
| Q3 2021 | $1,042,000 | -31.7% | 17,585 | 0.0% | 0.01% | -28.6% |
| Q2 2021 | $1,526,000 | -4.4% | 17,585 | -9.2% | 0.01% | 0.0% |
| Q1 2021 | $1,597,000 | -43.0% | 19,365 | -37.1% | 0.01% | -41.7% |
| Q4 2020 | $2,800,000 | +130.1% | 30,798 | +1.1% | 0.01% | +100.0% |
| Q3 2020 | $1,217,000 | +21.9% | 30,458 | +4.7% | 0.01% | +20.0% |
| Q2 2020 | $998,000 | +76.3% | 29,083 | +14.1% | 0.01% | +25.0% |
| Q1 2020 | $566,000 | – | 25,492 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |